Point72 Hong Kong’s Insys Therapeutics, Inc. INSY Stock Holding History

Point72 Hong Kong’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,607	Closed	-$23K	–	1418
2018 Q4	$23K	Buy	+6,607	New	+$45.9K	0.01%	438
2017 Q2	–	Sell	-5	Closed	–	–	1130
2017 Q1	$0	Sell	5 -752	-99%	-$8.01K	﹤0.01%	1126
2016 Q4	$7K	Buy	+757	New	+$8.55K	0.01%	693

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Point72 Hong Kong's INSY Position: Q1 2019 in Review

Point72 Hong Kong sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 6,607 shares — an estimated $23K sold.

Point72 Hong Kong first reported a position in INSY in Q4 2016 and held it in 3 quarters. The position peaked at $23K in Q4 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Point72 Hong Kong reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Point72 Hong Kong sold 6,607 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $23K.
Point72 Hong Kong first reported a position in Insys Therapeutics, Inc. in Q4 2016 and held it in 3 quarters.
Point72 Hong Kong's Insys Therapeutics, Inc. position peaked at $23K in Q4 2018.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Point72 Hong Kong's 13F filing for Q1 2019, filed 15 May 2019.